Table 1 Patient, tumor, and treatment characteristics
Parameter | Cohort (n = 70) |
|---|---|
Patients-no. | 70 |
Tumors (targets)-no. | 76 |
Follow-up time-median (range) | 15 (8–22) months |
Median age-median (range) | 74 (54–91) years |
Sex | |
M-no. (%) | 28 (40.0) |
F-no. (%) | 42 (60.0) |
Location | |
Right upper lobe-no. (%) | 18 (23.7) |
Right middle lobe-no. (%) | 4 (5.3) |
Right lower lobe-no. (%) | 14 (18.4) |
Left upper lobe-no. (%) | 14 (18.4) |
Left lower lobe-no. (%) | 26 (34.2) |
Central | 28 (36.8) |
Peripheral | 48 (63.2) |
Metastatic-no. (%) | 2 (2.9) |
Lung Primary-no. (%) | 68 (97.1) |
Histology | |
Adenocarcinoma | 40 (57.1) |
Squamous | 17 (24.3) |
NSCLC-NOS | 11 (15.7) |
Tumor Size-median (range) | 2.3 (0.6–5.5) cm |
≤3 cm | 53 (69.7) |
>3 cm | 23 (30.3) |
Median GTV (range) | 6.6 (0.3–150.4) cc |
Median PTV (range) | 20.8 (12.4–308.2) cc |
Median total dose (range) | 50 (25–60) Gy |
1 fraction (%) | 19 (27.1 %) |
3–8 fractions (%) | 51 (72.9 %) |